Vincerx Pharma, Inc. announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the treatment of diffuse large B cell lymphoma.
[Vincerx Pharma, Inc.]
Sorry, but the selected Zotpress account can't be found.
